Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and limb ischemia-reperfusion induced lung injury in severed finger replantation
ChiCTR2300075039Phase 4Not yet recruiting
- Sponsor
- Nanning Second People's Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in not applicable; "lung injury" is not a specific disease (2 arms), sponsored by Nanning Second People's Hospital. Primary endpoints: Incidence of postoperative lung injury, Oxygenation index (T0–T3) and 9 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on ChiCTR2300075039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075039.